ocugen_4C_LOGO (002).png
Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
31 mai 2024 08h36 HE | Ocugen
Established Medium Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Recommends Continuing with High-Dose Cohort Dosing with Concurrent Phase 2 Dosing MALVERN, Pa., May 31, 2024 ...
ocugen_4C_LOGO (002).png
Ocugen to Present at BIO International Convention 2024
29 mai 2024 07h15 HE | Ocugen
MALVERN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
ocugen_4C_LOGO (002).png
Ocugen Set to Join Russell 3000® Index Effective June 28, 2024
28 mai 2024 07h02 HE | Ocugen
MALVERN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
ocugen_4C_LOGO (002).png
Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
20 mai 2024 07h00 HE | Ocugen
MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
ocugen_4C_LOGO (002).png
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
15 mai 2024 06h30 HE | Ocugen
MALVERN, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
ocugen_4C_LOGO (002).png
Ocugen Provides Business Update with First Quarter 2024 Financial Results
14 mai 2024 08h00 HE | Ocugen
All three first-in-class modifier gene therapy product candidates currently in the clinic with OCU400 Phase 3 in progressOCU400 on track to meet 2026 Biologics License Application (BLA) and Market...
ocugen_4C_LOGO (002).png
Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
10 mai 2024 16h05 HE | Ocugen
MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
ocugen_4C_LOGO (002).png
Ocugen to Present at May 2024 Investor Conferences
10 mai 2024 07h45 HE | Ocugen
MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
ocugen_4C_LOGO (002).png
Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
03 mai 2024 07h30 HE | Ocugen
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
ocugen_4C_LOGO (002).png
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
02 mai 2024 07h15 HE | Ocugen
MALVERN, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...